Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906746 · ClinicalTrials.gov registry record · Early Phase 1
Ruxolitinib for Cancer Cachexia
A Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia, sponsored by Tu Dan.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04906746: Active Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia, sponsored by Tu Dan.
NCT04906746 is a Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia that is active but no longer recruiting, run by Tu Dan. The registered enrollment target is 10 participants, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04906746, a Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia, is active but no longer recruiting, sponsored by Tu Dan.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
Primary Outcome
To assess toxicity with use of Ruxolitinib in NSCLC (non-small cell lung cancer) cachexia patients, NCI's CTCAE v5.0 toxicity criteria will be used to measure Ruxolitinib-related side effects. Grade 3 or higher events will be recorded.
Conditions Studied
Interventions
- DRUG Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2025-12 |
| Phase | Early Phase 1 |
What the registry record for NCT04906746 still lists
NCT04906746 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. is the first listed.
NCT04906746 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04906746 about?
NCT04906746 is a clinical study titled "Ruxolitinib for Cancer Cachexia". To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
What is the current status of trial NCT04906746?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2022-02-23. Estimated completion is 2025-12.
What conditions does trial NCT04906746 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Cachexia.
What interventions are being tested in trial NCT04906746?
The interventions under investigation include: Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. (DRUG).
Who is sponsoring clinical trial NCT04906746?
This trial is sponsored by Tu Dan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906746 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04906746's enrollment target sits among peer trials
10 22nd of 23 higher than 1 of 23 other Stage IV Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
COMPLETED · Early Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI